Company Celladon Corp Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Therapies
100.0
%
| 13 | 100.0 % | 16 | 100.0 % | +16.98% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States, Ireland and United Kingdom
100.0
%
| 13 | 100.0 % | 16 | 100.0 % | +16.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Chief Tech/Sci/R&D Officer | 57 | 22-04-17 | |
General Counsel | - | 16-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Amit Sachdev
BRD | Director/Board Member | 56 | 19-04-14 |
Evan Loh
BRD | Director/Board Member | 65 | 17-09-17 |
Kim Sablich
BRD | Director/Board Member | 55 | 21-04-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,480,797 | 1,262,028 ( 85.23 %) | 0 | 85.23 % |
Company contact information
Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard
94306-1543, Palo Alto
+650 272 6138
http://www.eigerbio.comSector
1st Jan change | Capi. | |
---|---|---|
+31.80% | 49.46B | |
+1.11% | 42.58B | |
+48.94% | 42.49B | |
-5.26% | 29.09B | |
+12.59% | 26.61B | |
-23.61% | 18.64B | |
+7.32% | 13.16B | |
+30.84% | 12.55B | |
+23.87% | 12.1B |